InvestorsHub Logo
icon url

blue_skies

11/05/19 5:05 PM

#17 RE: blue_skies #16

why i am optimistic
Our Freedom Syringe Infusion System is also being utilized in multiple clinical trials associated with the development of new subcutaneous therapies, which is an important component of our long-term growth strategy.”

Higher then I expected but believe there will be a drop in Q4
Litigation costs increased to $0.9 million

I expect and am optimistic that KRMD will get some of the legal fees back?
has filed motions for reimbursement of court costs and attorneys’ fees subsequent to the receipt of both judgements.

Carefully managing investor expectations KUDOS
Growth was driven primarily by the Company’s continued success in expanding its presence in the Primary Immune Deficiency Disease (“PIDD”) and Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”) markets, as well as large orders from a domestic distributor, a new customer in Europe, and clinical trials. We cannot predict whether such large distributor orders or volume generally will continue in the future.
icon url

blue_skies

11/05/19 5:13 PM

#18 RE: blue_skies #16

after hours broke five
crazy